12 advances in cancer immunotherapy

Today marks White Out Cancer Day.

The Cancer Research Institute launched the observance four years ago, encouraging people to wear white to raise awareness of cancer immunotherapy and the need for additional research.

In conjunction with White Out Cancer Day — as well as Cancer Immunotherapy Month, observed every June — HemOnc Today presents 12 recent updates in cancer immunotherapy research.

  • ASCO named progress in immunotherapy for melanoma and other malignancies as the top cancer advance of the year. Read more
  • Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai Hospital in New York, discusses developments in using active immunotherapy to treat lymphoma and chronic lymphocytic leukemia. Watch here
  • First-line atezolizumab (Tecentriq; Genentech/Roche) appeared effective and safe for cisplatin-ineligible patients with metastatic urothelial cancer, according to data from the IMvigor210 phase 2 study. Read more
  • Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director of Roswell Park Cancer Institute and executive director of the institute’s Center for Immunotherapy, spoke to HemOnc Today about how new approaches have demonstrated potential to exploit the immune system during cancer treatment. Watch here
  • Treatment with sacituzumab govitecan (IMMU-132, Immunomedics) induced objective responses and appeared tolerable in patients with metastatic non–small cell lung cancer who received first-line platinum-based therapy. Read more
  • Ezra Cohen, MD, associate director and professor of medicine at Moores Cancer Center at UC San Diego, discusses the promise of immune-based strategies in head and neck cancer. Watch here
  • Binimetinib (MEK162, Array BioPharma) improved PFS and increased disease control compared with dacarbazine among patients with NRAS–mutant melanoma, according to results of the phase 3 NEMO study. Read more
  • Joseph Markowitz, MD, PhD, medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years. Watch here
  • Recurrent copy number gains to the genes that encode the PD-1 ligands appeared associated with PD-L1 expression in certain patients with cervical and vulvar squamous cell carcinoma. Read more
  • The FDA granted accelerated approval to atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Read more
  • David Bajor, MD, of the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, discusses the trajectory of immunotherapy in the treatment of melanoma. Watch here
  • Avelumab (MSB0010718C; Pfizer, Merck KGaA) induced durable responses in patients with metastatic Merkel cell carcinoma who experienced progression after chemotherapy. Read more

Today marks White Out Cancer Day.

The Cancer Research Institute launched the observance four years ago, encouraging people to wear white to raise awareness of cancer immunotherapy and the need for additional research.

In conjunction with White Out Cancer Day — as well as Cancer Immunotherapy Month, observed every June — HemOnc Today presents 12 recent updates in cancer immunotherapy research.

  • ASCO named progress in immunotherapy for melanoma and other malignancies as the top cancer advance of the year. Read more
  • Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai Hospital in New York, discusses developments in using active immunotherapy to treat lymphoma and chronic lymphocytic leukemia. Watch here
  • First-line atezolizumab (Tecentriq; Genentech/Roche) appeared effective and safe for cisplatin-ineligible patients with metastatic urothelial cancer, according to data from the IMvigor210 phase 2 study. Read more
  • Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director of Roswell Park Cancer Institute and executive director of the institute’s Center for Immunotherapy, spoke to HemOnc Today about how new approaches have demonstrated potential to exploit the immune system during cancer treatment. Watch here
  • Treatment with sacituzumab govitecan (IMMU-132, Immunomedics) induced objective responses and appeared tolerable in patients with metastatic non–small cell lung cancer who received first-line platinum-based therapy. Read more
  • Ezra Cohen, MD, associate director and professor of medicine at Moores Cancer Center at UC San Diego, discusses the promise of immune-based strategies in head and neck cancer. Watch here
  • Binimetinib (MEK162, Array BioPharma) improved PFS and increased disease control compared with dacarbazine among patients with NRAS–mutant melanoma, according to results of the phase 3 NEMO study. Read more
  • Joseph Markowitz, MD, PhD, medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years. Watch here
  • Recurrent copy number gains to the genes that encode the PD-1 ligands appeared associated with PD-L1 expression in certain patients with cervical and vulvar squamous cell carcinoma. Read more
  • The FDA granted accelerated approval to atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Read more
  • David Bajor, MD, of the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, discusses the trajectory of immunotherapy in the treatment of melanoma. Watch here
  • Avelumab (MSB0010718C; Pfizer, Merck KGaA) induced durable responses in patients with metastatic Merkel cell carcinoma who experienced progression after chemotherapy. Read more